260
Views
19
CrossRef citations to date
0
Altmetric
Review

Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives

, , &
Pages 127-140 | Published online: 21 Sep 2016

Figures & data

Figure 1 Pathophysiology of CF lung disease and potential therapies targeting the basic defect or the symptoms.

Note: In the absence of conclusive data on gene therapy, CFTR modulators are the most proximal therapy for CF currently in development.
Abbreviations: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; ENaC, epithelial sodium channel; mRNA, messenger RNA.
Figure 1 Pathophysiology of CF lung disease and potential therapies targeting the basic defect or the symptoms.

Figure 2 Predicted topology of CFTR protein.

Notes: It is composed of two repeated units made of a MSD followed by a NBD. The two repeated units are linked by a R domain. The MSDs consist of six hydrophobic transmembrane helices (or TMD). Several transmembrane helices contain one or more charged amino acids that control anion permeability. Extracellular loop 4 (between TMD7 and TMD8) contains two N-glycosylation sites.
Abbreviations: CFTR, cystic fibrosis transmembrane conductance regulator; MSD, membrane-spanning domain; NBD, nucleotide-binding domain; TMD: transmembrane domain; R, regulatory domain.
Figure 2 Predicted topology of CFTR protein.

Table 1 Classes of CFTR mutations

Figure 3 Overview of the most advance CFTR modulators in preclinical and clinical studies, with regard to the class of CFTR mutations and the primary defect of the corresponding mutant protein.

Abbreviations: CFTR, cystic fibrosis transmembrane conductance regulator; PTC, premature termination codon; EGCG, epigallocatechin gallate; ER, endoplasmic reticulum; Ub, ubiquitin; mRNA, messenger RNA.
Figure 3 Overview of the most advance CFTR modulators in preclinical and clinical studies, with regard to the class of CFTR mutations and the primary defect of the corresponding mutant protein.

Table 2 Mechanisms of action of pharmacological modulators of CFTR available to CF patients or under preclinical development as mono- and/or combitherapies for CF